25.09.2018 22:01:01
|
DGAP-News: MorphoSys Announces its Licensee Janssen has Initiated a Phase 3 Trial (PROTOSTAR) to Evaluate Guselkumab in Pediatric Psoriasis Patients
DGAP-News: MorphoSys AG / Key word(s): Study Planegg/Munich, Germany, September 25, 2018 MorphoSys Announces its Licensee Janssen has Initiated a Phase 3 Trial (PROTOSTAR) to Evaluate Guselkumab in Pediatric Psoriasis Patients MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC, has initiated a phase 3 clinical trial of guselkumab in pediatric patients suffering from chronic plaque psoriasis. According to clinicaltrials.gov, the trial, PROTOSTAR, is expected to enroll approximately 125 children between 6 and 18 years of age with plaque psoriasis and will evaluate the efficacy, safety and pharmacokinetics of guselkumab against etanercept and placebo. Guselkumab is a fully human anti-IL-23 monoclonal antibody developed by Janssen, and was generated utilizing MorphoSys's proprietary HuCAL antibody technology. Dr. Markus Enzelberger, Chief Scientific Officer of MorphoSys AG, said: "We are very pleased that our licensee Janssen has started phase 3 development for the treatment of chronic plaque psoriasis in children. If successful, we hope that this study will contribute to providing more therapeutic options to this patient group." Guselkumab (tradename Tremfya(R)) has been approved in the U.S., Canada, the European Union, and several other countries for the treatment of plaque psoriasis in adult patients, and in Japan for the treatment of both psoriasis and psoriatic arthritis. Moreover, guselkumab is currently being investigated in two phase 3 trials in psoriatic arthritis and also in a phase 2/3 clinical study program in Crohn's disease. More information about guselkumab clinical studies is available on clinicaltrials.gov.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group. Tremfya(R) is a trademark of Janssen Biotech, Inc.
MorphoSys AG Jochen Orlowski Dr. Claudia Gutjahr-Loeser Tel: +49 (0) 89 / 899 27-404 Additional features: Document: http://n.eqs.com/c/fncls.ssp?u=KWHWXOJKQE Document title: Media Release
25.09.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | MorphoSys AG |
Semmelweisstr. 7 | |
82152 Planegg | |
Germany | |
Phone: | +49 (0)89 899 27-0 |
Fax: | +49 (0)89 899 27-222 |
E-mail: | investors@morphosys.com |
Internet: | www.morphosys.com |
ISIN: | DE0006632003 |
WKN: | 663200 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |
|
727025 25.09.2018

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu MorphoSysmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu MorphoSysmehr Analysen
06.05.24 | MorphoSys Neutral | UBS AG | |
30.04.24 | MorphoSys Neutral | UBS AG | |
16.02.24 | MorphoSys Neutral | UBS AG | |
07.02.24 | MorphoSys Neutral | UBS AG | |
07.02.24 | MorphoSys Buy | UBS AG |